Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

[1]  Robert L Sutherland,et al.  PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality , 2010, International journal of cancer.

[2]  O. Olopade,et al.  Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer: Promising Clinical Target or Only a Marker? , 2010, Cancer journal.

[3]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[4]  H. Modjtahedi,et al.  Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. , 2009, Anti-cancer drugs.

[5]  W. Gradishar,et al.  New Molecular Classifications of Breast Cancer , 2009, CA: a cancer journal for clinicians.

[6]  W. Gerald,et al.  PIK3CA Mutation Associates with Improved Outcome in Breast Cancer , 2009, Clinical Cancer Research.

[7]  J. Hunt,et al.  KRAS Mutation Testing in Colorectal Cancer , 2009, Advances in anatomic pathology.

[8]  G. Hortobagyi,et al.  Management of breast cancer in the genome era. , 2009, Annual review of medicine.

[9]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Charles M. Perou,et al.  Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.

[11]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[12]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[13]  F. Schmitt,et al.  EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy , 2008, Expert review of molecular diagnostics.

[14]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Perou,et al.  Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.

[16]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Sanjay Goel,et al.  PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.

[18]  O. Fadare,et al.  Clinical and pathologic aspects of basal-like breast cancers , 2008, Nature Clinical Practice Oncology.

[19]  E. Van Cutsem,et al.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  C. Perou,et al.  Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer , 2008, Cancer investigation.

[21]  T. Nielsen,et al.  Are triple-negative tumours and basal-like breast cancer synonymous? , 2007, Breast Cancer Research.

[22]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[23]  Charles M Perou,et al.  EGFR associated expression profiles vary with breast tumor subtype , 2007, BMC Genomics.

[24]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[26]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[27]  E. Paish,et al.  Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression , 2007, Histopathology.

[28]  Mieke Schutte,et al.  Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines , 2007, Molecular Cancer Research.

[29]  M. Monden,et al.  Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women , 2007, Clinical Cancer Research.

[30]  H. Muss.  Targeted therapy for metastatic breast cancer. , 2006, The New England journal of medicine.

[31]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[32]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[33]  B. Iacopetta,et al.  PIK3CA mutations in breast cancer are associated with poor outcome , 2006, Breast Cancer Research and Treatment.

[34]  R. Hennekam,et al.  Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome , 2006, Nature Genetics.

[35]  Kam Y. J. Zhang,et al.  Germline KRAS mutations cause Noonan syndrome , 2006, Nature Genetics.

[36]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[37]  S. Lakhani,et al.  Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis , 2005, Breast Cancer Research.

[38]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[39]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[40]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[41]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[42]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[43]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[44]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[45]  Annuska M Glas,et al.  Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[48]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .

[49]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[50]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Ash A. Alizadeh,et al.  Towards a novel classification of human malignancies based on gene expression patterns , 2001, The Journal of pathology.

[52]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[53]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[54]  J. Benítez,et al.  Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.